引言过去10年中获得的大量循证医学证据充分证明了血管紧张素转换酶抑制剂(ACEI)治疗心血管病的价值。ACEI已被推荐用于高血压、心力衰竭、冠心病、心肌梗死的治疗及高危人群的二级预防,并写入国内外指南之中。但是,在临床实践与指南之间仍存在不小的差距。在指南明确列为Ⅰ类适应证的情况下,ACEI 在日常临床实践中应用仍远远不够,且剂量不足。本专家共识的编写目的,在于将 ACEI 用于心血管疾病的理念以及在不同临床情况下应用的证据和使用方法等归纳为一个共识性文件,供临床医师决策时参考,以进一步改善我国广大临床工作者临床应用 ACEI 的状 INTRODUCTION The substantial evidence-based medical evidence gained over the past decade is evidence of the value of angiotensin-converting enzyme inhibitors (ACEIs) in the treatment of cardiovascular disease. ACEI has been recommended for the treatment of hypertension, heart failure, coronary heart disease, myocardial infarction and secondary prevention of high-risk groups and is included in guidelines both at home and abroad. However, there is still a big gap between clinical practice and guidelines. In cases where the guidelines are clearly classified as Class I indications, the use of ACEI in daily clinical practice is far from adequate and the dose is inadequate. The purpose of the preparation of this expert consensus lies in the concept of ACEI for cardiovascular disease and the application of evidence in different clinical situations and the use of methods summarized as a consensus document for reference for clinicians to make decisions in order to further improve our clinical The clinical application of ACEI workers form